Dedication Acknowledgments About the Editor and Associate Editor Contributing Authors Introduction Prologue Historical Perspective of CrohnÆs Disease Wojciech Blonski, MD, PhD; David Kotlyar, MD; Ming V. Lin, MD; and Gary R. Lichtenstein, MD, FACP, FACG, AGAF Section I General Chapter 1 The Natural History of Inflammatory Bowel Disease Pietro G. Andres, MD and Lawrence S. Friedman, MD Chapter 2 Clinical Research in Inflammatory Bowel Disease: Placebo Response in Clinical Trials Chinyu Su, MD and James D. Lewis, MD, MSCE Chapter 3 The Role of the FDA in Drug Development in Inflammatory Bowel Disease Alan C. Moss, MD and Adam Cheifetz, MD Chapter 4 Utility of Animal Models for the Study and Treatment of Inflammatory Bowel Disease Ashish Chawla, MD and Kenneth Simpson, BVM&S, PhD Chapter 5 Pediatric Considerations in Medical Therapy in Patients With Inflammatory Bowel Disease Louis R. Ghanem, MD, PhD and Robert N. Baldassano, MD Chapter 6 The Limitations of Applying Evidence-Based Medicine to Inflammatory Bowel Disease: What We Do Not Learn From Clinical Trials Joshua R. Korzenik, MD and Corey A. Siegel, MD Chapter 7 Disease Modifiers in Inflammatory Bowel Disease Jaime A. Oviedo, MD and Francis A. Farraye, MD, MSc, FACP, FACG Chapter 8 Fertility and Pregnancy in Inflammatory Bowel Disease Jeffry A. Katz, MD and Vinita Elizabeth Jacob, MD Chapter 9 Medication Adherence in Inflammatory Bowel Disease Sunanda Kane, MD, MSPH, FACG, FACP, AGAF Section II Medications Chapter 10 Mesalamine for Maintenance Therapy in Ulcerative Colitis: How Much, How Long? Miles P. Sparrow, MD, MBBS, FRACP; Wee-Chian Lim, MD, MBBS, MMed, MRCP; and Stephen B. Hanauer, MD Chapter 11 Antibiotic Use in the Treatment of CrohnÆs Disease Manuel Mendizabal, MD; Wojciech Blonski, MD, PhD; David Kotlyar, MD; and Gary R. Lichtenstein, MD, FACP, FACG, AGAF Chapter 12 Corticosteroids in CrohnÆs Disease Lene Riis, MD and Pia Munkholm, MD, DMSCi Chapter 13 Oral Budesonide for Inflammatory Bowel Disease Gordon R. Greenberg, MD, FRCP(C) Chapter 14 6-Mercaptopurine and Azathioprine in CrohnÆs Disease Mark T. Osterman, MD and Gary R. Lichtenstein, MD, FACP, FACG, AGAF Chapter 15 Methotrexate in the Treatment of CrohnÆs Disease Ellen J. Scherl, MD, FACP, AGAF; Arun Swaminath, MD; Ryan Urquhart Warren, MD; and Harrison Lakehomer, BA Chapter 16 Calcineurin Inhibitors (Cyclosporine A, Tacrolimus, and Sirolimus) and Mycophenolate Mofetil in CrohnÆs Disease Gerassimos J. Mantzaris, MD, PhD, AGAF Chapter 17 Infliximab in CrohnÆs Disease Lawrence W. Comerford, MD and Stephen J. Bickston, MD, AGAF Chapter 18 Anti-TNFa Therapy From Symptoms to Molecules: Impact of Individual Variability on Anti-TNFa Optimization Strategies Ellen J. Scherl, MD, FACP, AGAF Chapter 19 Novel Biological Therapies for CrohnÆs Disease &nbs
